

asx announcement

Mesoblast Results Highlighted At Key Orthopaedic Conferences

Melbourne, Australia; 27 February 2009: Australia's regenerative medicine company Mesoblast Limited (ASX:MSB;PINK:MBLTY) today announced that three separate papers disclosing clinical and preclinical trial results were presented this week to orthopaedic specialists attending the 55th annual meeting of the American Academy of Orthopedic Surgeons (AAOS) and the Orthopedic Research Society (ORS). The meetings, underway in Las Vegas, attract an estimated 15,000 orthopedic healthcare professionals from around the world.

A major highlight at the AAOS was the invited presentation given by Mr Richard de Steiger, the Principal Investigator of Mesoblast's long bone non-union clinical trial at The Royal Melbourne Hospital. Mr de Steiger presented the positive results from the company's successful trial in 10 patients treated with the proprietary adult stem cells for non-healing fractures of the tibia and femur.

At the ORS, Dr Tony Goldschlager of Monash University in Melbourne presented results from preclinical trials showing that Mesoblast's allogeneic, or "off-the-shelf", cells were safe and highly effective for interbody fusion of the cervical spine in the neck.

Also at the ORS, Professor Peter Ghosh presented preclinical results which showed that a single injection of Mesoblast's allogeneic cells into knee joints with pre-existing osteoarthritis reduced disease progression and supported reconstitution of knee joint cartilage six months after administration.

Mesoblast will continue to ensure that its clinical achievements and cutting edge research are highlighted and recognised at respected and prestigious conferences, meetings attended by key opinion leaders, and peer-reviewed publications.

About Mesoblast

Mesoblast Limited (ASX:MSB; PINK:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones. www.mesoblast.com

For further information, please contact:

Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61 (03) 9639 6036
M: +61 (0) 419 228 128
E: julie.meldrum@mesoblast.com